Hypercoagulability in Cushing's syndrome: Prevalence, pathogenesis and treatment

Clinical Endocrinology

Volumn 78, Issue 4, 2013, Pages 481-488

  Van Der Pas, R ^a   Leebeek, F W G ^a   Hofland, L J ^a   De Herder, W W ^a   Feelders, R A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; CABERGOLINE; CORTICOTROPIN; DEXAMETHASONE; ENOXAPARIN; FIBRINOGEN; GLUCOCORTICOID; HEPARIN; KETOCONAZOLE; MESSENGER RNA; NADROPARIN; PASIREOTIDE; PLASMIN; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; VON WILLEBRAND FACTOR;

ANTICOAGULANT THERAPY; BLOOD CLOTTING; CUSHING DISEASE; CUSHING SYNDROME; DEEP VEIN THROMBOSIS; ENDOCRINE SURGERY; FIBRINOLYSIS; GENE EXPRESSION; HOSPITALIZATION; HUMAN; HYPERCOAGULABILITY; HYPERCORTISOLISM; IMMOBILIZATION; LUNG EMBOLISM; NONHUMAN; OUTCOME ASSESSMENT; PARTIAL THROMBOPLASTIN TIME; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW (TOPIC); THROMBOCYTE ADHESION; THROMBOSIS PREVENTION; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; TRANSSPHENOIDAL SURGERY; VENOUS THROMBOEMBOLISM;

CUSHING SYNDROME; HEMOSTASIS; HUMANS; INCIDENCE; MODELS, BIOLOGICAL; PREVALENCE; PREVENTIVE MEDICINE; THROMBOPHILIA; VENOUS THROMBOEMBOLISM;

EID: 84875186967     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/cen.12094     Document Type: Review

References (61)

1. Clayton, R.N., Raskauskiene, D., Reulen, R.C., et al,. (2011) Mortality and morbidity in Cushing's disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature. Journal of Clinical Endocrinology and Metabolism, 96, 632-642.
2. Dekkers, O.M., Biermasz, N.R., Pereira, A.M., et al,. (2007) Mortality in patients treated for Cushing's disease is increased, compared with patients treated for nonfunctioning pituitary macroadenoma. Journal of Clinical Endocrinology and Metabolism, 92, 976-981.
3. Lindholm, J., Juul, S., Jorgensen, J.O., et al,. (2001) Incidence and late prognosis of cushing's syndrome: a population-based study. Journal of Clinical Endocrinology and Metabolism, 86, 117-123.
4. Boscaro, M., Barzon, L., Fallo, F., et al,. (2001) Cushing's syndrome. Lancet, 357, 783-791.
5. Newell-Price, J., Bertagna, X., Grossman, A.B., et al,. (2006) Cushing's syndrome. Lancet, 367, 1605-1617.
6. Colao, A., Pivonello, R., Spiezia, S., et al,. (1999) Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. Journal of Clinical Endocrinology and Metabolism, 84, 2664-2672.
7. Pereira, A.M., Tiemensma, J., &, Romijn, J.A., (2010) Neuropsychiatric disorders in Cushing's syndrome. Neuroendocrinology, 92 (Suppl 1), 65-70.
8. Tiemensma, J., Biermasz, N.R., Middelkoop, H.A., et al,. (2010) Increased prevalence of psychopathology and maladaptive personality traits after long-term cure of Cushing's disease. Journal of Clinical Endocrinology and Metabolism, 95, E129-141.
9. Johnson, M.D., Woodburn, C.J., &, Vance, M.L., (2003) Quality of life in patients with a pituitary adenoma. Pituitary, 6, 81-87.
10. Webb, S.M., Badia, X., Barahona, M.J., et al,. (2008) Evaluation of health-related quality of life in patients with Cushing's syndrome with a new questionnaire. European Journal of Endocrinology, 158, 623-630.
11. van Aken, M.O., Pereira, A.M., Biermasz, N.R., et al,. (2005) Quality of life in patients after long-term biochemical cure of Cushing's disease. Journal of Clinical Endocrinology and Metabolism, 90, 3279-3286.
12. Biller, B.M., Grossman, A.B., Stewart, P.M., et al,. (2008) Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. Journal of Clinical Endocrinology and Metabolism, 93, 2454-2462.
13. Nieman, L.K., (2002) Medical therapy of Cushing's disease. Pituitary, 5, 77-82.
14. Stuijver, D.J., van Zaane, B., Feelders, R.A., et al,. (2011) Incidence of Venous Thromboembolism in Patients with Cushing's Syndrome: A Multicenter Cohort Study. Journal of Clinical Endocrinology and Metabolism, 96, 3525-3532.
15. Van Zaane, B., Nur, E., Squizzato, A., et al,. (2009) Hypercoagulable state in Cushing's syndrome: a systematic review. Journal of Clinical Endocrinology and Metabolism, 94, 2743-2750.
16. Koutroumpi, S., Daidone, V., Sartori, M.T., et al,. (2012) Venous thromboembolism in patients with Cushing's syndrome: need of a careful investigation of the prothrombotic risk profile. Pituitary, [Epub ahead of print].
17. Yoshimura, S., Ago, T., Kitazono, T., et al,. (2005) Cerebral sinus thrombosis in a patient with Cushing's syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 76, 1182-1183.
18. Boscaro, M., Sonino, N., Scarda, A., et al,. (2002) Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism, 87, 3662-3666.
19. Trementino, L., Arnaldi, G., Appolloni, G., et al,. (2010) Coagulopathy in Cushing's syndrome. Neuroendocrinology, 92 (Suppl 1), 55-59.
20. Semple, P.L., &, Laws, E.R. Jr, (1999) Complications in a contemporary series of patients who underwent transsphenoidal surgery for Cushing's disease. Journal of Neurosurgery, 91, 175-179.
21. Naess, I.A., Christiansen, S.C., Romundstad, P., et al,. (2007) Incidence and mortality of venous thrombosis: a population-based study. Journal of Thrombosis and Haemostasis, 5, 692-699.
22. Rees, D.A., Hanna, F.W., Davies, J.S., et al,. (2002) Long-term follow-up results of transsphenoidal surgery for Cushing's disease in a single centre using strict criteria for remission. Clinical Endocrinology (Oxford), 56, 541-551.
23. Patil, C.G., Lad, S.P., Harsh, G.R., et al,. (2007) National trends, complications, and outcomes following transsphenoidal surgery for Cushing's disease from 1993 to 2002. Neurosurgical Focus, 23, E7.
24. Pezzulich, R.A., &, Mannix, H. Jr, (1970) Immediate complications of adrenal surgery. Annals of Surgery, 172, 125-130.
25. Akl, E.A., Labedi, N., Terrenato, I., et al,. (2011) Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer. Cochrane Database Systematic Review, CD009447.
26. Garcia, D., &, Quintana, D., (2011) Thrombosis and malignancy: a case-based review. Seminars in Hematology, 48, 259-263.
27. van der Pas, R., de Bruin, C., Leebeek, F.W., et al,. (2012) The hypercoagulable state in Cushing's disease is associated with increased levels of procoagulant factors and impaired fibrinolysis, but is not reversible after short-term biochemical remission induced by medical therapy. Journal of Clinical Endocrinology and Metabolism, 97, 1303-1310.
28. Manetti, L., Bogazzi, F., Giovannetti, C., et al,. (2010) Changes in coagulation indexes and occurrence of venous thromboembolism in patients with Cushing's syndrome: results from a prospective study before and after surgery. European Journal of Endocrinology, 163, 783-791.
29. Terzolo, M., Allasino, B., Bosio, S., et al,. (2004) Hyperhomocysteinemia in patients with Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism, 89, 3745-3751.
30. Casonato, A., Pontara, E., Boscaro, M., et al,. (1999) Abnormalities of von Willebrand factor are also part of the prothrombotic state of Cushing's syndrome. Blood Coagulation & Fibrinolysis, 10, 145-151.
31. Kastelan, D., Dusek, T., Kraljevic, I., et al,. (2009) Hypercoagulability in Cushing's syndrome: the role of specific haemostatic and fibrinolytic markers. Endocrine, 36, 70-74.
32. Erem, C., Nuhoglu, I., Yilmaz, M., et al,. (2009) Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels. Journal of Endocrinological Investigation, 32, 169-174.
33. Patrassi, G.M., Sartori, M.T., Viero, M.L., et al,. (1992) The fibrinolytic potential in patients with Cushing's disease: a clue to their hypercoagulable state. Blood Coagulation & Fibrinolysis, 3, 789-793.
34. De Groot, P.G., &, Meijers, J.C., (2010) Physiology and diagnostics of hemostasis. In Hematology (ed., B. Lowenberg,). de Tijdstroom, Utrecht, the Netherlands, pp. 215-236.
35. Boffa, M.B., Hamill, J.D., Maret, D., et al,. (2003) Acute phase mediators modulate thrombin-activable fibrinolysis inhibitor (TAFI) gene expression in HepG2 cells. Journal of Biological Chemistry, 278, 9250-9257.
36. van Zonneveld, A.J., Curriden, S.A., &, Loskutoff, D.J., (1988) Type 1 plasminogen activator inhibitor gene: functional analysis and glucocorticoid regulation of its promoter. Proceedings of the National Academy of Sciences USA, 85, 5525-5529.
37. Halleux, C.M., Declerck, P.J., Tran, S.L., et al,. (1999) Hormonal control of plasminogen activator inhibitor-1 gene expression and production in human adipose tissue: stimulation by glucocorticoids and inhibition by catecholamines. Journal of Clinical Endocrinology and Metabolism, 84, 4097-4105.
38. Morange, P.E., Aubert, J., Peiretti, F., et al,. (1999) Glucocorticoids and insulin promote plasminogen activator inhibitor 1 production by human adipose tissue. Diabetes, 48, 890-895.
39. Kerachian, M.A., Cournoyer, D., Harvey, E.J., et al,. (2009) Effect of high-dose dexamethasone on endothelial haemostatic gene expression and neutrophil adhesion. Journal of Steroid Biochemistry and Molecular Biology, 116, 127-133.
40. Huang, L.Q., Whitworth, J.A., &, Chesterman, C.N., (1995) Effects of cyclosporin A and dexamethasone on haemostatic and vasoactive functions of vascular endothelial cells. Blood Coagulation & Fibrinolysis, 6, 438-445.
41. Brotman, D.J., Girod, J.P., Posch, A., et al,. (2006) Effects of short-term glucocorticoids on hemostatic factors in healthy volunteers. Thrombosis Research, 118, 247-252.
42. Ikkala, E., Myllyla, G., Pelkonen, R., et al,. (1985) Haemostatic parameters in Cushing's syndrome. Acta Medica Scandinavica, 217, 507-511.
43. Guimaraes, A.H., de Bruijne, E.L., Lisman, T., et al,. (2009) Hypofibrinolysis is a risk factor for arterial thrombosis at young age. British Journal of Haematology, 145, 115-120.
44. Lisman, T., de Groot, P.G., Meijers, J.C., et al,. (2005) Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood, 105, 1102-1105.
45. Federici, A.B., Bader, R., Pagani, S., et al,. (1989) Binding of von Willebrand factor to glycoproteins Ib and IIb/IIIa complex: affinity is related to multimeric size. British Journal of Haematology, 73, 93-99.
46. Daidone, V., Boscaro, M., Pontara, E., et al,. (2011) New insight into the hypercoagulability of Cushing's syndrome. Neuroendocrinology, 93, 121-125.
47. Hoke, M., Kyrle, P.A., Minar, E., et al,. (2005) Tissue factor pathway inhibitor and the risk of recurrent venous thromboembolism. Thrombosis and Haemostasis, 94, 787-790.
48. Abumiya, T., Yamaguchi, T., Terasaki, T., et al,. (1995) Decreased plasma tissue factor pathway inhibitor activity in ischemic stroke patients. Thrombosis and Haemostasis, 74, 1050-1054.
49. Ambrosi, B., Sartorio, A., Pizzocaro, A., et al,. (2000) Evaluation of haemostatic and fibrinolytic markers in patients with Cushing's syndrome and in patients with adrenal incidentaloma. Experimental and Clinical Endocrinology & Diabetes, 108, 294-298.
50. Mertens, I., &, Van Gaal, L.F., (2002) Obesity, haemostasis and the fibrinolytic system. Obesity Reviews, 3, 85-101.
51. Targher, G., Zoppini, G., Moghetti, P., et al,. (2010) Disorders of coagulation and hemostasis in abdominal obesity: emerging role of fatty liver. Seminars in Thrombosis and Hemostasis, 36, 41-48.
52. Stein, P.D., Beemath, A., &, Olson, R.E., (2005) Obesity as a risk factor in venous thromboembolism. American Journal of Medicine, 118, 978-980.
53. Papanicolaou, D.A., Tsigos, C., Oldfield, E.H., et al,. (1996) Acute glucocorticoid deficiency is associated with plasma elevations of interleukin-6: does the latter participate in the symptomatology of the steroid withdrawal syndrome and adrenal insufficiency? Journal of Clinical Endocrinology and Metabolism, 81, 2303-2306.
54. Levi, M., (2010) The coagulant response in sepsis and inflammation. Hamostaseologie, 30 (10-12), 14-16.
55. Healy, A.M., &, Gelehrter, T.D., (1994) Induction of plasminogen activator inhibitor-1 in HepG2 human hepatoma cells by mediators of the acute phase response. Journal of Biological Chemistry, 269, 19095-19100.
56. Donati, M.B., &, Lorenzet, R., (2012) Thrombosis and cancer: 40 years of research. Thrombosis Research, 129, 348-352.
57. Green, K.B., &, Silverstein, R.L., (1996) Hypercoagulability in cancer. Hematology/oncology Clinics of North America, 10, 499-530.
58. Dal Bo Zanon, R., Fornasiero, L., Boscaro, M., Cappellato, G., Fabris, F., &, Girolami, A., (1982) Increased factor VIII associated activities in Cushing's syndrome: a probable hypercoagulable state. Thrombosis and Haemostasis, 47, 116-117.
59. Feelders, R.A., de Bruin, C., Pereira, A.M., et al,. (2010) Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease. New England Journal of Medicine, 362, 1846-1848.
60. Gould, M.K., Garcia, D.A., Wren, S.M., et al,. (2012) Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 141, e227S-277S.
61. Black, P.M., Zervas, N.T., &, Candia, G.L., (1987) Incidence and management of complications of transsphenoidal operation for pituitary adenomas. Neurosurgery, 20, 920-924.